GenSight Biologics, a privately-owned French company, has raised €32 million in a Series A round from a group of venture capital funds to develop a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON), a serious eye disorder. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine
